A meta-analysis of eleven studies, encompassing data from over 19,000 patients with type 2 diabetes and obesity, indicates that bariatric surgery offers superior cardiovascular protection and reduces mortality compared to glucagon-like peptide-1 receptor agonists (GLP-1 RA), commonly known as GLP-1 drugs.
The findings, published in Obesity Surgery, challenge the increasingly prominent role of GLP-1 medications like semaglutide and tirzepatide in the treatment of obesity and related metabolic disorders. Researchers assessed long-term outcomes, focusing on cardiovascular events and overall mortality rates. The meta-analysis demonstrated a more substantial benefit from metabolic and bariatric surgery (MBS) in mitigating these risks.
While GLP-1 drugs have gained significant attention for their weight-loss capabilities and potential cardiovascular benefits, the study suggests these benefits are less pronounced than those achieved through surgical intervention. The research highlights that bariatric surgery, despite being a more invasive procedure, provides a more durable and impactful effect on cardiovascular health for individuals with both type 2 diabetes and obesity.
The study acknowledges that some patients undergoing bariatric surgery may experience insufficient weight loss or weight regain, potentially leading to a resurgence of obesity-related health problems. In these cases, GLP-1 analogues are being explored as adjunct therapies, administered either before or after the surgical procedure, to optimize metabolic outcomes. A systematic review and meta-analysis published in Langenbeck’s Archives of Surgery in October 2025 examined the use of GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement.
The increasing popularity of drugs like semaglutide and tirzepatide has prompted discussion regarding their potential impact on the demand for bariatric surgery, as reported by JAMA Network. However, the latest meta-analysis reinforces the distinct advantages of surgery in terms of long-term cardiovascular protection and mortality reduction.
